SIRPA and hematologic disorder: TTI-621, a SIRPα-Fc (human IgG1 Fc) fusion protein that blocks the CD47-SIRPα interaction, is being tested in patients with hematologic malignancies and solid tumors (NCT02663518), while TTI-622 (a SIRPα-Fc (human IgG4 Fc) fusion protein is being evaluated in a Phase I clinical trial in relapsed or refractory lymphoma or myeloma (NCT03530683).